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Abstract
Human parechoviruses (HPeV) cause symptoms ranging from severe neonatal infections tomild gastrointestinal and respiratory disease. Use of
PCR and genotyping has markedly improved the detection rate of HPeV but has simultaneously raised questions about the clinical relevance of
positive tests. This retrospective study correlates positive HPeV1 or HPeV3 PCR tests in stools from children with their symptoms to
determine clinical relevance. Children with HPeV1- or HPeV3-positive stool samples, as detected by real time RT-PCR and direct genotyping,
between 2004 and 2008 were selected. Clinical data were retrospectively collected from the patient’s ﬁles and results were compared. One
hundred and thirty-eight children with positive HPeV1 (n = 112) or HPeV3 (n = 26) stool samples were identiﬁed. Signiﬁcantly more
HPeV3-infected children were neonates or infants younger than 6 months of age. Meningitis or sepsis-like illnesses were diagnosed most
frequently and were found in signiﬁcantly younger children. Almost half of HPeV1-infected children had an underlying disease. Mild
gastrointestinal disease was seenmost frequently in these children. There was no clear correlation between viral load (Ct value) and severity of
symptoms. In conclusion, HPeV3 detected by PCR in stool samples is associated with clinically relevant disease. For HPeV1, a positive stool
sample is mainly associated with symptoms in children with underlying disease.
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Abstract
Members of the Dobrava–Belgrade virus (DOBV) species are hantaviruses carried by different Apodemus mice as reservoir hosts and causing
haemorrhagic fever with renal syndrome (HFRS) in humans. In Central Europe, the Kurkino genotype of DOBV, associated with the striped
ﬁeld mouse, Apodemus agrarius, is prevalent. This paper presents the ﬁrst extensive study of the serological and molecular diagnostics,
epidemiology and clinics of DOBV-Kurkino infections in Central Europe. Serum samples from 570 German patients living in the habitat of
A. agrarius (north and northeast Germany) and exhibiting febrile disease, were analysed. All samples were tested by ELISA, subsets of
samples were also analysed by immunoblot, neutralization assay, and RT-PCR. A group of 86 individuals was conﬁrmed as DOBV-infected.
The virus neutralization assay allowed a reliable identiﬁcation of DOBV antibodies during both acute and convalescent phases of infection.
However, differentiation of relevant DOBV genotypes was not possible by neutralization test but required molecular analysis. Whereas
DOBV IgM antibodies tend to persist in the infected organism, RNAaemia seems to be short. Nucleotide sequences were ampliﬁed from
four patients, and their analysis demonstrated infection by DOBV-Kurkino. With respect to the initial results, the high degree of identity of
local patient-derived and A. agrarius-derived virus sequences may allow a closer allocation of the geographical place where the human
infection occurred. In contrast to moderate/severe HFRS caused by the DOBV genotypes Dobrava or Sochi, all available data showed a mild
clinical course of HFRS caused by DOBV-Kurkino infection without lethal outcomes.
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Abstract
Granulomas may develop as a response to a local antigenic trigger, leading to the activation of macrophages and T-lymphocytes. Primary
immunodeﬁciency (PID) is associated with the development of extensive cutaneous granulomas, whose aetiology remains unknown. We
performed high-throughput sequencing of the transcriptome of cutaneous granuloma lesions on two consecutive index cases, and RT-PCR
in a third consecutive patient. The RA27/3 vaccine strain of rubella virus—the core component of a universally used paediatric vaccine—was
present in the cutaneous granuloma of these three consecutive PID patients. Controls included the healthy skin of two patients,
non-granulomatous cutaneous lesions of patients with immunodeﬁciency, and skin biopsy samples of healthy individuals, and were negative.
Expression of viral antigens was conﬁrmed by immunoﬂuorescence. Persistence of the rubella vaccine virus was also demonstrated in
granuloma lesions sampled 4–5 years earlier. The persistence of the rubella virus vaccine strain in all three consecutive cutaneous
granuloma patients with PID strongly suggests a causal relationship between rubella virus and granuloma in this setting.
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Abstract
In the Lao People’s Democratic Republic (PDR), mumps is not a notiﬁable disease and mumps vaccine is currently not included in the
routine childhood immunization programme. In order to assess the burden of disease, we investigated the seroprevalence of
mumps-speciﬁc IgG antibodies across four provinces. In addition, we genetically characterized mumps viruses from the past 3 years from
several outbreaks and single cases. Blood and/or throat swabs from suspected cases were investigated for speciﬁc IgM antibodies or viral
RNA. Mumps cases occurred between March and November in 2011–2013 and 5- to 15-year-olds were most affected. Four sequences
from an outbreak in the north of Lao PDR in 2011 were identical and belonged to genotype G. Eight sequences from two outbreaks and two
individual cases from 2012 and 2013 belonged to genotype J. In addition, sera collected from 2379 healthy infants and school pupils aged
between 9 months and 19 years and from pregnant women aged between 16 and 46 years were investigated for mumps-speciﬁc IgG.
Overall, 58.2% were positive, 39.5% were negative and the remaining 2.3% were equivocal. The seropositivity increased with age, with the
lowest percentage found in <1-year-old infants (9.1%) and the highest in the cohort of pregnant women (69.2%). More female subjects than
male subjects were seropositive (60.4 vs. 54.9%). There were some differences between the locations. Mumps should be a notiﬁable disease
in Lao PDR in order to get more accurate case numbers and cost estimates for public health-care, and vaccination of children and high-risk
groups should be considered.
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Abstract
At 30 years into the HIV infection epidemic, the optimal antiretroviral (ARV) regimen for infected patients with cancer remains unknown.
We therefore sought to retrospectively study different ARV regimens used in this population. Data from HIV-infected patients seen at The
University of Texas MD Anderson Cancer Center in Houston, Texas, USA, from 2001 to 2012 were reviewed. Patients received nucleoside
reverse transcriptase inhibitors (NRTIs) plus protease inhibitors (PIs), non-NRTIs (NNRTIs), integrase strand-transfer inhibitors (INSTIs),
or combinations of these. A total of 154 patients were studied. Most patients were male (80%), white (51%) and had haematological
malignancies (HMs) (58%). NRTIs were combined with PIs (37%), NNRTIs (32%), INSTIs (19%) or combinations of these (11%). INSTIs
were the most commonly used in patients with HM and in those receiving high-dose steroids or topoisomerase inhibitors (p <0.05).
Side-effects occurred in 35%, 14%, 3% and 6% of patients receiving PIs, NNRTIs, INSTIs and combinations, respectively (p 0.001). Grade 3–4
adverse events were uncommon. Multivariate logistic regression analysis demonstrated that INSTIs and NNRTIs were nine times (95%
conﬁdence interval (CI), 1.4–50.8) and 11 times (95% CI, 1.9–64.7) more likely to be effective at 6 months, respectively, than PIs. This is the
largest reported analysis studying different ARV regimens in HIV-infected cancer patients. Combinations that included PIs were the least
favourable. NNRTIs and INSTIs had comparable efﬁcacy, but INSTIs appeared to be the better tolerated ARVs in patients with HM or those
receiving various chemotherapeutic agents.
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Abstract
We assessed the persistence of hepatitis B surface antigen antibody (anti-HBs) and immune memory in a cohort of 571 teenagers vaccinated
against hepatitis B as infants, 17 years earlier. Vaccinees were followed-up in 2003 and in 2010 (i.e. 10 years and 17 years after primary
vaccination, respectively).When tested in 2003, 199 vaccinees (group A) had anti-HBs <10 mIU/mL andwere boosted, 372 (group B) were not
boosted because they had anti-HBs ≥10 mIU/mL (n = 344) or refused booster (n = 28) despite anti-HBs <10 mIU/mL. In 2010, 72.9% (416/
571) of participants had anti-HBs ≥10 mIU/mL (67.3% in group A vs. 75.8% in group B; p 0.03). The geometric mean concentrations (GMCs)
were similar in both groups. Between 2003 and 2010, anti-HBs concentrations in previously boosted individuals markedly declined with GMC
dropping from486 to27.7 mIU/mL (p<0.001). Fifteen vaccinees showed amarked increaseof antibody, possibly due tonatural booster. In 2010,
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96 individuals (37of groupAand59of groupB)with anti-HBs<10 mIU/mLwere boosted; all vaccinees of the former group and all but twoof the
latter had an anamnestic response. Post-booster GMC was higher in group B (895.6 vs. 492.2 mIU/mL; p 0.039). This ﬁnding shows that the
immune memory for HBsAg persists beyond the time at which anti-HBs disappears, conferring long-term protection.
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Abstract
Nucleos(t)ide analogue (NUC) resistance is an important clinical risk resulting from long-termtherapy in chronichepatitis B (CHB)management.
DiscontinuationofNUCs isa feasible strategy toreduceresistance.Weaimedtoobserve theoutcomesafterNUCwithdrawal inHBeAg-positive
CHB patients. A total of 97 patients (11 patients with HBsAg loss and 86 patients with sustained HBeAg seroconversion) were enrolled. HBV
DNA levels and alanine aminotransferase (ALT) levels weremonitored regularly after discontinuation. Relapse was deﬁned as HBVDNA levels
>2000 IU/mL inat least twodeterminationsmorethan4 weeksapart.HBeAgseroconversionwasachievedwithin48 weeks (interquartile range
(IQR), 24–72 weeks). The time on consolidation therapy was 96 weeks (IQR, 84–144 weeks). No relapses occurred for HBsAg loss patients.
Evidence of relapse was observed in 9.3% of HBeAg seroconversion patients. All relapse cases occurred within 48 weeks after discontinuation.
The time to relapse was 33  15 weeks. Elevation of HBVDNA and ALT levels over baseline were only observed in 12.5% of relapse patients.
Therewerenosigniﬁcantdifferences inbaselinecharacteristics (sex,HBVgenotype, ageorALT levels)or timeonconsolidation therapybetween
patients with relapse or sustained response. NUC discontinuation in HBeAg-positive CHB patients is feasible after achieving HBeAg
seroconversion at aminimumof24 weeks.There is furtherbeneﬁt toprolonging the timeonconsolidation therapy to reduce relapse.More than
48 weeks of sustained response is a predictive marker for long-term sustained response.
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Abstract
HBsAg-negative/HBcAb-positive haematopoietic stem cell transplant (HSCT) recipients are at high risk of hepatitis B virus (HBV)
reactivation. Allogeneic HSCT recipients from years 2000 to 2010 were evaluated in order to study the impact of being HBsAg-negative/
HBcAb-positive in this population. Overall, 137 of 764 patients (18%) were HBsAg-negative/HBcAb-positive before HSCT. Overall survival,
non-relapse mortality (NRM), acute and chronic graft-vs.-host disease were similar in HBcAb-positive and HBcAb-negative patients.
Reactivation occurred in 14 patients (10%) within a median of 19 months after HSCT (range 9–77). Cause-speciﬁc hazard for reactivation
was decreased in the case of an HBV-immune/exposed donor (HRadjusted = 0.12; 95% CI, 0.02–0.96; p 0.045) and increased in patients who
received rituximab treatment (HRadjusted = 2.91; 95%CI, 0.77–10.97; p 0.11). Competing risk analyses documented a protective role of an
HBV-immune/exposed donor (p 0.041) and an increased probability associated with the length of treatment with cyclosporine (p <0.001)
and treatment with rituximab (but not with low-dose rituximab prophylaxis, p <0.001 at each landmark point). No differences in overall
survival and NRM were found between patients with and without HBV reactivation. The donor’s immunity was independently and
consistently associated with a decreased risk of HBV reactivation, while rituximab and cyclosporine treatments increased the probability.
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Abstract
The overall vaccine effectiveness of the monovalent rotavirus vaccine in an observational, prospective, multicentre, hospital-based case–
control study in Belgium (RotaBel) was 90%. However, rotavirus genotype and co-infecting pathogens are important parameters to take into
account when assessing vaccine effectiveness. In this study we speciﬁcally investigated the effect of rotavirus genotypes and co-infecting
pathogens on vaccine effectiveness of the monovalent vaccine. In addition, we also investigated the effect of co-infecting pathogens on
disease severity. From February 2008 to June 2010 stool samples of rotavirus gastroenteritis cases of a random sample of 39 Belgian
hospitals were collected and subsequently genotyped. Fisher’s exact tests were performed to investigate the relationships between
rotavirus genotype, co-infecting pathogens and disease severity. The vaccine effectiveness of a full series of the monovalent rotavirus vaccine
against hospitalized rotavirus gastroenteritis caused by G1P[8] rotavirus strains was 95% (95% CI 77.5–98.7). Against G2P[4], the vaccine
effectiveness was 85% (95% CI: 63.7–93.8). G4P[8]- and G3P[8]-speciﬁc vaccine effectiveness was 90% (95% CI 19.2–98.7) and 87% (95% CI
5.2 to 98.4), respectively. A post-hoc analysis showed that the genotype distribution was signiﬁcantly related to the vaccination status
(p <0.001), whereby G2P[4] strains were proportionally more prevalent in vaccinated cases than in unvaccinated cases. No statistical
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1040–1046
CMI Online-Only Abstracts 1045
associations were found between co-infection status and vaccination status, Vesikari severity score or rotavirus genotype. The high vaccine
effectiveness against the individual genotypes implies robust protection of the monovalent rotavirus vaccine against hospitalized rotavirus
gastroenteritis caused by the major human rotavirus genotypes. The prevalence of G2P[4] requires continued monitoring.
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Abstract
Enterovirus 71 (EV71) infection has a wide variety of clinical manifestations, from no symptoms to fatal disease. Host immune response may
be a determinant of disease severity. We investigated the association of polymorphisms in three pattern recognition receptor (PRR) genes
—toll-like receptor 3 (TLR3) (rs3775291), retinoic acid-inducible gene I (RIG-I) (rs10813831) and melanoma differentiation-associated gene
5 (MDA5) (rs1990760)—with the severity of EV71 infection. Polymorphisms of candidate genes in 87 EV71-infected patients and 57
asymptomatic controls were detected. Binary logistic regression analysis revealed statistically signiﬁcant differences in polymorphism of
MDA5 (rs1990760) between patients with severe EV71 infection and asymptomatic controls in an additive model (OR 0.424, 95% CI 0.213–
0.845, p 0.015) and a dominant model (OR 0.256, 95% CI 0.103–0.635, p 0.003). Polymorphism of MDA5 (rs1990760) (OR 0.399, 95% CI
0.199–0.798, p 0.009) was found to be associated with the severity of EV71 infection with the analysis of ordinal logistic regression. These
results indicated the association between MDA5 (rs1990760) polymorphism and an increased risk of a severe EV71 infection in Chinese
children, which offers potential for investigating the innate immune mechanism of EV71 infection and identifying at-risk infants, for whom a
preventive strategy may reduce the severity of EV71 infection.
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